Secretome Therapeutics
Last verified 2026-06-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $30.0Mattributed |
|---|---|
| Latest round | series-a, $30.0M, 2026-05-27attributed |
| Founded | unknown |
| Headquarters | US |
| Industry | healthcare |
| Stage | series-a |
| Website | secretometx.com |
Secretome Therapeutics develops regenerative medicines from neonatal cardiac progenitor cells, with lead programs STM-01 and STM-2 for heart failure including HFpEF. It targets patients with serious cardiac disease lacking good options. Its neonatal cells give near-zero variability and reportedly triple the potency of adult cells.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-05-27 | series-a | $30.0M | undisclosed |
Detected tech stack
bootstrap 5.3.3, cdnjs, cloudflare, express, hsts, http/3, jquery 3.7.1, jquery cdn, jsdelivr, nginx, node.js, slick 1.9.0
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $30.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $30.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | secretometx.com, read 2026-06-16 |
| Description | self-reported | secretometx.com, read 2026-06-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.